MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-11-2023
TCR2 Therapeutics Total Liabilities 2011-2026 | TCRR
Annual Total Liabilities TCR2 Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 67.4 M | 41.9 M | 9.65 M | 8.08 M | 215 M | 48.4 M | 30.1 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 215 M | 8.08 M | 60.1 M |
Quarterly Total Liabilities TCR2 Therapeutics
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50.2 M | 67.4 M | 74.4 M | 81.8 M | 67.9 M | 41.9 M | 40.5 M | 39.2 M | 46.4 M | 9.65 M | 9.65 M | 9.65 M | 9.65 M | 8.08 M | 8.08 M | 8.08 M | 8.08 M | 5.9 M | 5.9 M | 5.9 M | 5.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 81.8 M | 5.9 M | 28.8 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M |  USA |
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Allakos
ALLK
|
74.8 M | - | - | $ 28.6 M | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 4.57 | -0.22 % | $ 11 B |  Australia |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Compugen Ltd.
CGEN
|
18.5 M | $ 2.65 | -2.93 % | $ 248 M |  Israel |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
6.77 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
4.9 M | $ 0.88 | - | $ 6.47 M | China |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
455 M | $ 22.5 | -0.75 % | $ 3.73 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Applied Therapeutics
APLT
|
72 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Galapagos NV
GLPG
|
171 M | $ 27.55 | -3.08 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
2.02 B | $ 25.89 | -3.36 % | $ 16 B |  Danmark |
 |
Avenue Therapeutics
ATXI
|
1.1 M | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
17.6 M | - | 5.93 % | $ 314 M |  Canada |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | Israel |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
38.9 M | - | 17.91 % | $ 11.1 M | USA |
 |
Atreca
BCEL
|
76.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioNTech SE
BNTX
|
2.76 B | $ 100.4 | -1.63 % | $ 27.2 B | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
137 M | - | -4.8 % | $ 255 M | USA |
 |
Innoviva
INVA
|
383 M | $ 23.23 | -1.94 % | $ 1.57 B | USA |
 |
Innate Pharma S.A.
IPHA
|
151 M | $ 1.45 | 3.57 % | $ 235 M | France |
 |
Aquestive Therapeutics
AQST
|
194 M | $ 4.07 | -0.61 % | $ 435 M | USA |
 |
Inventiva S.A.
IVA
|
226 M | $ 4.96 | -1.1 % | $ 138 M | France |
 |
Jaguar Health
JAGX
|
57 M | $ 0.23 | -5.27 % | $ 536 K | USA |
 |
Arcutis Biotherapeutics
ARQT
|
243 M | $ 22.56 | -3.13 % | $ 2.87 B | USA |
 |
KalVista Pharmaceuticals
KALV
|
338 M | $ 26.71 | 38.8 % | $ 1.44 B | Britain |
 |
Autolus Therapeutics plc
AUTL
|
411 M | $ 1.4 | -5.74 % | $ 373 M | Britain |
 |
Kamada Ltd.
KMDA
|
32 M | $ 8.15 | - | $ 260 M | Israel |
 |
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 2.88 | -1.03 % | $ 4.74 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
3.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |